Literature DB >> 32203142

Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model.

Stefanie Kreutmair1,2,3, Cathrin Klingeberg1, Teresa Poggio1, Geoffroy Andrieux2,4, Alexander Keller1,3, Cornelius Miething1,2,3, Marie Follo1, Dietmar Pfeifer1,3, Khalid Shoumariyeh1,2,3, Claudia Lengerke5, Irene Gonzalez-Menendez6, Falko Fend6, Robert Zeiser1,2,3, Suzanne D Turner7, Leticia Quintanilla-Martinez6, Melanie Boerries2,3,4, Justus Duyster1,2,3, Anna L Illert8,9,10.   

Abstract

While cancer stem cells are well established in certain hematologic and solid malignancies, their existence in T cell lymphoma is unclear and the origin of disease is not fully understood. To examine the existence of lymphoma stem cells, we utilized a mouse model of anaplastic large cell lymphoma. Established NPM-ALK+ lymphomas contained heterogeneous cell populations ranging from mature T cells to undifferentiated hematopoietic stem cells. Interestingly, CD4-/CD8- double negative (DN) lymphoma cells aberrantly expressed the T cell receptor α/β chain. Serial transplantation of sorted CD4/CD8 and DN lymphoma subpopulations identified lymphoma stem cells within the DN3/DN4 T cell population, whereas all other subpopulations failed to establish serial lymphomas. Moreover, transplanted lymphoma DN3/DN4 T cells were able to differentiate and gave rise to mature lymphoma T cells. Gene expression analyses unmasked stem-cell-like transcriptional regulation of the identified lymphoma stem cell population. Furthermore, these lymphoma stem cells are characterized by low CD30 expression levels, which might contribute to limited long-term therapeutic success in patients treated with anti-CD30-targeted therapies. In summary, our results highlight the existence of a lymphoma stem cell population in a NPM-ALK-driven CD30+ mouse model, thereby giving the opportunity to test innovative treatment strategies developed to eradicate the origin of disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32203142      PMCID: PMC7685983          DOI: 10.1038/s41375-020-0789-x

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

Review 1.  An overview of the intrathymic intricacies of T cell development.

Authors:  Divya K Shah; Juan Carlos Zúñiga-Pflücker
Journal:  J Immunol       Date:  2014-05-01       Impact factor: 5.422

2.  Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

Authors:  Craig H Moskowitz; Jan Walewski; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Simonetta Viviani; Veronika Bachanova; Anna Sureda; Teresa McClendon; Connie Lee; Julie Lisano; John Sweetenham
Journal:  Blood       Date:  2018-09-28       Impact factor: 22.113

Review 3.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

4.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

5.  CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells.

Authors:  Xiao Luo; Yulian Yang; Fanhui Kong; Long Zhang; Kun Wei
Journal:  Int J Pharm       Date:  2019-04-16       Impact factor: 5.875

6.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

7.  Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Authors:  Olaf Merkel; Frank Hamacher; Robert Griessl; Lisa Grabner; Ana-Iris Schiefer; Nicole Prutsch; Constance Baer; Gerda Egger; Michaela Schlederer; Peter William Krenn; Tanja Nicole Hartmann; Ingrid Simonitsch-Klupp; Christoph Plass; Philipp Bernhard Staber; Richard Moriggl; Suzanne D Turner; Richard Greil; Lukas Kenner
Journal:  J Pathol       Date:  2015-04-27       Impact factor: 7.996

8.  Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.

Authors:  S Gerboth; E Frittoli; A Palamidessi; F C Baltanas; M Salek; J Rappsilber; C Giuliani; F Troglio; Y Rolland; G Pruneri; S Kreutmair; I Pallavicini; M Zobel; M Cinquanta; S Minucci; C Gomez; E Santos; A L Illert; G Scita
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

9.  Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Authors:  Lukas Kenner; Olaf Merkel; Nicole Prutsch; Elisabeth Gurnhofer; Tobias Suske; Huan Chang Liang; Michaela Schlederer; Simone Roos; Lawren C Wu; Ingrid Simonitsch-Klupp; Andrea Alvarez-Hernandez; Christoph Kornauth; Dario A Leone; Jasmin Svinka; Robert Eferl; Tanja Limberger; Astrid Aufinger; Nitesh Shirsath; Peter Wolf; Thomas Hielscher; Christina Sternberg; Fritz Aberger; Johannes Schmoellerl; Dagmar Stoiber; Birgit Strobl; Ulrich Jäger; Philipp B Staber; Florian Grebien; Richard Moriggl; Mathias Müller; Giorgio G Inghirami; Takaomi Sanda; A Thomas Look; Suzanne D Turner
Journal:  Leukemia       Date:  2018-08-21       Impact factor: 11.528

10.  Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression.

Authors:  Claudius Klein; Anabel Zwick; Sandra Kissel; Christine Ulrike Forster; Dietmar Pfeifer; Marie Follo; Anna Lena Illert; Sarah Decker; Thomas Benkler; Heike Pahl; Robert A J Oostendorp; Konrad Aumann; Justus Duyster; Christine Dierks
Journal:  J Exp Med       Date:  2016-02-01       Impact factor: 14.307

View more
  3 in total

1.  NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.

Authors:  Stefanie Kreutmair; Lena Johanna Lippert; Cathrin Klingeberg; Corinna Albers-Leischner; Salome Yacob; Valeria Shlyakhto; Tony Mueller; Alina Mueller-Rudorf; Chuanjiang Yu; Sivahari Prasad Gorantla; Cornelius Miething; Justus Duyster; Anna Lena Illert
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

2.  Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.

Authors:  Elisa Redl; Raheleh Sheibani-Tezerji; Crhistian de Jesus Cardona; Patricia Hamminger; Gerald Timelthaler; Melanie Rosalia Hassler; Maša Zrimšek; Sabine Lagger; Thomas Dillinger; Lorena Hofbauer; Kristina Draganić; Andreas Tiefenbacher; Michael Kothmayer; Charles H Dietz; Bernard H Ramsahoye; Lukas Kenner; Christoph Bock; Christian Seiser; Wilfried Ellmeier; Gabriele Schweikert; Gerda Egger
Journal:  Life Sci Alliance       Date:  2020-12-11

Review 3.  Application of double-negative T cells in haematological malignancies: recent progress and future directions.

Authors:  Xingchi Chen; Dongyao Wang; Xiaoyu Zhu
Journal:  Biomark Res       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.